Trial · NCT00689221
Results by group145
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 145
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) Time | Cilengitide + Temozolomide + Radiotherapy | 26.3 | 95% Confidence Interval 23.8 to 28.8 | Months | |
| Overall Survival (OS) Time | Temozolomide + Radiotherapy | 26.3 | 95% Confidence Interval 23.9 to 34.7 | Months | |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Cilengitide + Temozolomide + Radiotherapy | PFS Time: Investigator read | 13.5 | 95% Confidence Interval 10.8 to 15.9 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Temozolomide + Radiotherapy | PFS Time: Investigator read | 10.7 | 95% Confidence Interval 8.1 to 13.3 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Cilengitide + Temozolomide + Radiotherapy | PFS Time: Independent read | 10.6 | 95% Confidence Interval 8.2 to 13.4 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Temozolomide + Radiotherapy | PFS Time: Independent read | 7.9 | 95% Confidence Interval 5.9 to 12.5 | Months |
| Maximum Observed Plasma Concentration (Cmax) | Cilengitide + Temozolomide + Radiotherapy | 167363.2 | Standard Deviation 368301.11 | nanogram per milliliter (ng/mL) | |
| Time to Maximum Plasma Concentration (Tmax) | Cilengitide + Temozolomide + Radiotherapy | 1.029 | Standard Deviation 0.401 | hours | |
| Area Under the Plasma Concentration Curve From Time 0 to 6 Hours (AUC [0-6]) After Dose | Cilengitide + Temozolomide + Radiotherapy | 295171.2 | Standard Deviation 198050.62 | hour*ng/mL | |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Cilengitide + Temozolomide + Radiotherapy | Global Health Status (n=71, 92) | 54.34 | Standard Deviation 25.58 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Temozolomide + Radiotherapy | Global Health Status (n=71, 92) | 55.43 | Standard Deviation 27.02 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Cilengitide + Temozolomide + Radiotherapy | Physical Functioning (n=71, 92) | 65.70 | Standard Deviation 33.01 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Temozolomide + Radiotherapy | Physical Functioning (n=71, 92) | 67.46 | Standard Deviation 31.19 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Cilengitide + Temozolomide + Radiotherapy | Role Functioning (n=71, 92) | 56.34 | Standard Deviation 37.31 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Temozolomide + Radiotherapy | Role Functioning (n=71, 92) | 56.34 | Standard Deviation 35.19 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Cilengitide + Temozolomide + Radiotherapy | Emotional Functioning (n=71, 93) | 67.49 | Standard Deviation 30.58 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Temozolomide + Radiotherapy | Emotional Functioning (n=71, 93) | 67.00 | Standard Deviation 27.29 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Cilengitide + Temozolomide + Radiotherapy | Cognitive Functioning (n=70, 93) | 64.05 | Standard Deviation 29.16 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Temozolomide + Radiotherapy | Cognitive Functioning (n=70, 93) | 65.41 | Standard Deviation 31.40 | units on a scale |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores | Cilengitide + Temozolomide + Radiotherapy | Social Activity (n=71, 93) | 56.34 | Standard Deviation 36.77 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00689221/results